{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=pomalidomide&page=6", "query": { "intervention": "pomalidomide", "page": 6 }, "page_size": 10 }, "pagination": { "page": 6, "page_size": 10, "total_count": 204, "total_pages": 21, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=pomalidomide&page=7&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=pomalidomide&page=5&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-21T19:15:49.815Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04508790", "title": "Leflunomide, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Plasma Cell Myeloma", "Refractory Plasma Cell Myeloma" ], "interventions": [ { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Leflunomide", "type": "DRUG" }, { "name": "Pomalidomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 29, "start_date": "2020-11-24", "completion_date": "2027-02-14", "has_results": false, "last_update_posted_date": "2026-05-29", "last_synced_at": "2026-10-21T19:15:49.815Z", "location_count": 8, "location_summary": "Duarte, California • Huntington Beach, California • Lancaster, California + 5 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Huntington Beach", "state": "California" }, { "city": "Lancaster", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Newport Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04508790" }, { "nct_id": "NCT00669578", "title": "CC-4047 in Treating Patients With Myelofibrosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Chronic Myeloproliferative Disorders", "Secondary Myelofibrosis" ], "interventions": [ { "name": "CC-4047", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 77, "start_date": "2008-05", "completion_date": "2019-12-12", "has_results": true, "last_update_posted_date": "2019-12-30", "last_synced_at": "2026-10-21T19:15:49.815Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00669578" }, { "nct_id": "NCT01946152", "title": "Pomalidomide, Dexamethasone, and Filgrastim-sndz in Treating Patients With Relapsed or Refractory Multiple Myeloma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Multiple Myeloma-Light Chain Only", "Recurrent Plasma Cell Myeloma", "Refractory Plasma Cell Myeloma" ], "interventions": [ { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Filgrastim-sndz", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pomalidomide", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 21, "start_date": "2014-03-05", "completion_date": "2020-03-18", "has_results": true, "last_update_posted_date": "2021-07-30", "last_synced_at": "2026-10-21T19:15:49.815Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01946152" }, { "nct_id": "NCT06948084", "title": "Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Multiple Myeloma", "Refractory Multiple Myeloma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Marrow Biopsy", "type": "PROCEDURE" }, { "name": "Carfilzomib", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Daratumumab and Recombinant Human Hyaluronidase", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "FDG-Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Pomalidomide", "type": "DRUG" }, { "name": "Teclistamab", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 80, "start_date": "2027-05-22", "completion_date": "2028-02-28", "has_results": false, "last_update_posted_date": "2026-10-20", "last_synced_at": "2026-10-21T19:15:49.815Z", "location_count": 27, "location_summary": "Coeur d'Alene, Idaho • Post Falls, Idaho • Sandpoint, Idaho + 21 more", "locations": [ { "city": "Coeur d'Alene", "state": "Idaho" }, { "city": "Post Falls", "state": "Idaho" }, { "city": "Sandpoint", "state": "Idaho" }, { "city": "Bloomington", "state": "Illinois" }, { "city": "Canton", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT06948084" }, { "nct_id": "NCT02415153", "title": "Pomalidomide in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neurofibromatosis Type 1", "Recurrent Childhood Brain Stem Glioma", "Recurrent Childhood Visual Pathway Glioma", "Recurrent Primary Central Nervous System Neoplasm", "Refractory Primary Central Nervous System Neoplasm" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Pomalidomide", "type": "DRUG" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": "20 Years", "sex": "ALL", "summary": "3 Years to 20 Years" }, "enrollment_count": 29, "start_date": "2015-07-14", "completion_date": "2020-05-27", "has_results": false, "last_update_posted_date": "2022-04-25", "last_synced_at": "2026-10-21T19:15:49.815Z", "location_count": 12, "location_summary": "Los Angeles, California • Palo Alto, California • Washington D.C., District of Columbia + 9 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02415153" }, { "nct_id": "NCT03651128", "title": "Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "bb2121", "type": "BIOLOGICAL" }, { "name": "Daratumumab", "type": "DRUG" }, { "name": "Pomalidomide", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Bortezomib", "type": "DRUG" }, { "name": "Ixazomib", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Carfilzomib", "type": "DRUG" }, { "name": "Elotuzumab", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 386, "start_date": "2019-04-16", "completion_date": "2026-04-13", "has_results": false, "last_update_posted_date": "2026-06-22", "last_synced_at": "2026-10-21T19:15:49.815Z", "location_count": 36, "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 26 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03651128" }, { "nct_id": "NCT00463385", "title": "A Phase II Study of Pomalidomide in Myelofibrosis With Myeloid Metaplasia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Myelofibrosis With Myeloid Metaplasia", "Myeloid Metaplasia", "Myelofibrosis" ], "interventions": [ { "name": "Pomalidomide", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Placebo to pomalidomide", "type": "DRUG" }, { "name": "Placebo to prednisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 88, "start_date": "2007-04-01", "completion_date": "2013-12-31", "has_results": true, "last_update_posted_date": "2019-11-20", "last_synced_at": "2026-10-21T19:15:49.815Z", "location_count": 6, "location_summary": "Los Angeles, California • Rochester, Minnesota • New York, New York + 2 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00463385" }, { "nct_id": "NCT03227432", "title": "An Exploratory Study to Evaluate the Combination of Elotuzumab and Nivolumab With and Without Pomalidomide in Relapsed Refractory Multiple Myeloma", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Pomalidomide", "type": "DRUG" }, { "name": "Elotuzumab", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2018-12", "completion_date": "2024-12-31", "has_results": false, "last_update_posted_date": "2018-08-14", "last_synced_at": "2026-10-21T19:15:49.815Z", "location_count": 3, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03227432" }, { "nct_id": "NCT07772024", "title": "Inobrodib, Pomalidomide and Dexamethasone Versus Standard Available Therapy in Relapsed or Refractory Multiple Myeloma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Multiple Myeloma Refractory", "Multiple Myeloma in Relapse" ], "interventions": [ { "name": "InoPd", "type": "DRUG" }, { "name": "Investigator's choice of SAT", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "CellCentric Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 450, "start_date": "2026-08", "completion_date": "2031-11", "has_results": false, "last_update_posted_date": "2026-08-19", "last_synced_at": "2026-10-21T19:15:49.815Z", "location_count": 1, "location_summary": "Miami, Florida", "locations": [ { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT07772024" }, { "nct_id": "NCT06892522", "title": "A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Etentamig", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Daratumumab", "type": "DRUG" }, { "name": "Carfilzomib", "type": "DRUG" }, { "name": "Mezigdomide", "type": "DRUG" }, { "name": "Iberdomide", "type": "DRUG" }, { "name": "ABBV-2001", "type": "DRUG" }, { "name": "Pomalidomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 602, "start_date": "2025-06-30", "completion_date": "2036-03", "has_results": false, "last_update_posted_date": "2026-10-19", "last_synced_at": "2026-10-21T19:15:49.815Z", "location_count": 15, "location_summary": "Duarte, California • Irvine, California • San Francisco, California + 11 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06892522" } ] }